Expression and functional diversity of the glucagon-like peptide-1 receptor across tumor types.

ABSTRACT:

Purpose

Glucagon-like peptide-1 receptor (GLP-1R) agonists are widely used to treat type 2 diabetes mellitus (T2DM) and obesity. Emerging evidence suggests potential links between GLP-1R signaling and cancer risk or progression, but its role in tumor biology remains unclear. This study investigated GLP-1R expression and prognostic value across multiple cancer types using large-scale genomic datasets.

Methods

We analyzed GLP-1R mRNA expression using data from The Cancer Genome Atlas (TCGA), Genotype-Tissue Expression (GTEx), and the Human Protein Atlas. Expression patterns in tumors were compared to normal tissues, including samples from rapid autopsies. Survival analyses were conducted across cancer types, and GLP-1R gene alterations were assessed via cBioPortal.

Results<

SUBMITTER: Alba MM 

PROVIDER: S-EPMC12779865 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature